TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8576747
Drug: Continuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous oxytocin administration (conventional continuous intravenous infusion)
Study: 2131793
Drug: HBI (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBI (sequential hemibody radiation with vincristine and prednisone)
Study: 773486
Drug: guanethidine and
Normalized name: guanethidine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanethidine and oxprenolol combination
Study: 26341358
Drug: Tele-rehabilitation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tele-rehabilitation intervention for 3 months, exercise 5 days a week using an iPad-based system, weekly video-conferencing with tele-therapists
Study: 24257410
Drug: Self-help app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Self-help app based on acceptance and commitment therapy and mindfulness-based cognitive behavioural therapy
Study: 21788542
Drug: Cranberry capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules, 500 mg twice daily
Study: 21788542
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX), 480 mg once daily
Study: 12639647
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (no active treatment).
Study: 10831274
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg/day) administered orally for 7 days prior to surgery
Study: 9386863
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/sqm day 1; fluorouracil 370 mg/sqm and L-folinic acid 100 mg/sqm days 1-3 administered every three weeks
Study: 9386863
Drug: Prolonged 5FU/L-FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged 5FU/L-FA schedule (5 days)
Study: 3001519
Drug: Intranasal alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal alpha 2-interferon (5 X 10(6) IU)
Study: 25016303
Drug: WHELD intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHELD intervention (comprehensive staff training on person-centred care, activities, and psychotropic medication use)
Study: 19618831
Drug: Lidocaine without
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine without infusion (Group IV)
Study: 19618831
Drug: Lidocaine without
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine without infusion and restart infusion before propofol (Group VI)
Study: 19618831
Drug: Saline without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline without infusion (Group III)
Study: 17888016
Drug: Implant-supported single-tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported single-tooth replacements with different augmentation procedures
Study: 10223775
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (200 mg carbamazepine tablet 3 times a day)
Study: 10223775
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (200 mg carbamazepine tablet 3 times a day)
Study: 8574859
Drug: Microwaved spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwaved spinach (150 g, 4.3 g dietary fibre)
Study: 8574859
Drug: Microwaved spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwaved spinach (250 g, 7.2 g dietary fibre)
Study: 721788
Drug: Prazepam in
Normalized name: Product containing prazepam in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazepam in divided doses
Study: 27757733
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg for 1 week, then 50 mg for 3 weeks, then eplerenone 50 mg for 1 month)
Study: 27757733
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg for 1 week, then 50 mg for 3 weeks, then spironolactone 50 mg for 1 month)
Study: 27757733
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet for 1 week, then 2 tablets for 3 weeks, then spironolactone 50 mg for 1 month)
Study: 20737243
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Cu/day (copper sulfate) for 2 months
Study: 17691886
Drug: Combination cessation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cessation medications
Study: 17691886
Drug: Behavioral counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral counseling and combination pharmacotherapy
Study: 31257613
Drug: Camelina sativa
Normalized name: CAMELINA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina sativa oil (CSO) providing 10 g/day alpha-linolenic acid (ALA)
Study: 29273470
Drug: IsaGenesis soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: IsaGenesis soft gel formulation
Study: 29273470
Drug: Product B
Normalized name: Product base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product B powdered capsule
Study: 26854478
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) for 16 weeks
Study: 22298802
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral bolus of 600,000 IU vitamin D₃
Study: 21146054
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with 6 mg of hyperbaric or hypobaric bupivacaine (RQ group)
Study: 21146054
Drug: Combined sciatic-femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic-femoral nerve block with 800 mg of 1.6% lidocaine with epinephrine (CFI group)
Study: 18020004
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy for low-risk tumours
Study: 18020004
Drug: Brachytherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy and hormonal therapy
Study: 16684855
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg conjugated estrogens + 2.5 mg medroxyprogesterone acetate (n = 9)
Study: 15252820
Drug: Sertraline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-150 mg daily)
Study: 15252820
Drug: Paroxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-60 mg daily)
Study: 15252820
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and Paroxetine
Study: 11119088
Drug: Immunohistochemistry using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemistry using labelled antibody to vinculin
Study: 25854019
Drug: Flunarizine hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine hydrochloride capsules orally
Study: 23970774
Drug: Self-administered paper-based
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered paper-based interview (SAPI)
Study: 9494172
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy for stroke prevention
Study: 3463544
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 400 mg enoxacin
Study: 3463544
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 3 g amoxicillin
Study: 26500075
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) using 100 mg/m2 of cisplatin for 90 min
Study: 24772619
Drug: Intraoperative intrapelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intrapelvic chemotherapy with hyperthermia (cisplatin at a dose of 150 mg, duration 60 minutes, temperature 44-45 degrees C)
Study: 24772619
Drug: Intraoperative intrapelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intrapelvic chemotherapy with hyperthermia
Study: 24772619
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intraoperative intrapelvic chemotherapy with hyperthermia)
Study: 18923067
Drug: MK-0777 (benzodiazepine-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0777 (benzodiazepine-like agent with selective activity at GABA(A) receptors containing alpha(2) or alpha(3) subunits)
Study: 9586597
Drug: Long-term medical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medical therapy for BPH
Study: 7635032
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of antiepileptic drugs
Study: 779871
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (transfusion support with or without androgens)
Study: 30853517
Drug: ESP Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESP Group (n = 30) received ultrasound-guided bilateral ESP block with 0.25% bupivacaine 20 mL
Study: 25280910
Drug: High contact
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High contact force (CF) ≥22 g
Study: 25280910
Drug: Low contact
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low contact force (CF) <22 g
Study: 21602718
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) at a mean dose of 16 mg/kg/d
Study: 11190708
Drug: Hydromorphone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (4 mg slow-release)
Study: 1462022
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide (320 micrograms day‐1)
Study: 3882368
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of blood glucose (SMBG) confirmed symptoms of hypoglycemia in all children and detected asymptomatic hypoglycemia (BG <= 40 mg/dl) in 11 children.
Study: 29763609
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of oxytocin following cervical ripening balloon expulsion
Study: 28101753
Drug: Zolpidem combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem combined with paroxetine (combined treatment group, n = 45)
Study: 23761390
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg on days 1-3, 20 mg on days 4-24, 10 mg on days 25-28)
Study: 16340629
Drug: Endoscopic hemoclip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic hemoclip treatment
Study: 10825787
Drug: Topical Mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Mometasone Furoate
Study: 6389909
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of dihydroergotamine plus 5000 IU of sodium heparin (DHE 5000)
Study: 6389909
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of dihydroergotamine plus 2500 IU heparin (DHE 2500)
Study: 6389909
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of heparin (HEP 5000)
Study: 6389909
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of dihydroergotamine (DHE 0.5)
Study: 29089267
Drug: Bismuth-based therapy
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based therapy (esomeprazole 20mg b.i.d and Pylera 3 tablets q.i.d)
Study: 29089267
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (esomeprazole 20mg plus amoxicillin 1,000mg, clarithromycin 500mg and tinidazole 500mg, all b.i.d.)
Study: 29089267
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (esomeprazole 20mg plus amoxicillin 1,000mg for 5 days followed by esomeprazole 20mg plus clarithromycin 500mg and tinidazole 500mg for 5 days, all b.i.d.)
Study: 24713367
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal vaccine
Study: 16864164
Drug: Adjuvant CMF-type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CMF-type chemotherapy (CT)
Study: 14620302
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment controls (G3)
Study: 1736548
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin and orbital radiotherapy (Group 1)
Study: 1736548
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin alone (Group 2)
Study: 6704502
Drug: TRM-HCT combination
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRM-HCT combination tablets
Study: 6704502
Drug: TRM-HCT combination
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRM-HCT combination capsules
Study: 6704502
Drug: TRM-HCT combination
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRM-HCT combination product
Study: 27780819
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of whey protein per hour (PULSE)
Study: 27780819
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g of whey protein at 0 h and 12 g of whey protein at 7 h postexercise (BOLUS)
Study: 27780819
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of maltodextrin per hour (placebo)
Study: 23618598
Drug: Cognitive Bias
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Bias Modification of Interpretations (CBM-I) training, administered by parents over three consecutive evenings
Study: 16750207
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of testosterone undecanoate and estradiol valerate (2 mg daily)
Study: 16750207
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (testosterone + estradiol)
Study: 11158692
Drug: 4% cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% cromolyn cream
Study: 9988054
Drug: Paroxetine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine up to 50 mg/day (n = 55)
Study: 9988054
Drug: Fluoxetine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine up to 80 mg/day (n = 54)
Study: 9988054
Drug: Paroxetine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine and Fluoxetine
Study: 8306736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AusP and conventional auscultation (ConA)
Study: 2903059
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine 2 HCl
Study: 4436447
Drug: Oral cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cephradine (2 g) with probenecid (1 g)
Study: 4436447
Drug: Intramuscular cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular cephradine (1 or 2 g) with probenecid (1 g)
Study: 4436447
Drug: Oral cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cephradine (500 mg) in fasting subjects
Study: 4436447
Drug: Oral cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cephradine (500 mg) in fed subjects
Study: 31337174
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline infusion at 1 mL/second (slow speed, A group)
Study: 31337174
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline infusion at 3 mL/second (rapid speed, B group)
Study: 24915562
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 125 mg every 12 hours during phototherapy
Study: 22336311
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pituitrin (0.01 - 0.03 U/min) added to conventional treatment
Study: 22336311
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (antibiotics, fluid resuscitation, glucocorticoids, organ support, dopamine 1-15 µg/(kg·min), norepinephrine 0.5-2 µg/(kg·min))
Study: 12759489
Drug: Omalizumab (0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (0.016 mg/kg/IgE every 4 weeks)
Study: 27886247
Drug: Moxibustion (MG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion (MG, n=15)
Study: 19755414
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg for 4 days)
Study: 16958712
Drug: Maternal/social role
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal/social role preparation
Study: 12515132
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (once, 48 hours before operation)
Study: 12515132
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (twice, 96 hours and 48 hours before operation)
Study: 10832472
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg IVIG on the first day of life
Study: 3371858
Drug: Betamethasone (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (6.0 mg for the first 5 days, 4.5 mg for the following week, and then 3.0 mg)
Study: 27039954
Drug: Naloxone (opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (opioid blocker)
Study: 26349124
Drug: Oral-B Pulsar
Normalized name: Oral-B Pulsar 3D White Luxe Pulsar Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Pulsar manual brush (OBP)
Study: 21664512
Drug: Mifepristone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 5 mg daily for three cycles
Study: 21664512
Drug: Mifepristone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 5 mg every other day for three cycles
Study: 18294410
Drug: Intraperitoneal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal tramadol 100 mg
Study: 11121720
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (3 or 6 mg/d)
Study: 11121720
Drug: Control diets
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diets (0.7/1.6/6.0 mg/d)
Study: 8594164
Drug: Short-term drug
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term drug abuse treatment (23-day duration)
Study: 1695312
Drug: Isradipine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (7.5 mg b.i.d.)
Study: 293493
Drug: Continuing therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing therapy for a total of six years
Study: 293493
Drug: Stopping therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping therapy after three years
Study: 31349945
Drug: CoQ10 and
Normalized name: Daily Energy Vitamin B12 + CoQ10 and Goji Berry Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 and Vitamin E (alone or in combination)
Study: 24246597
Drug: Kangaroo care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo care (KC) for 2 hours daily between days of life 5 to 10
Study: 19349317
Drug: Intravenous reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours)
Study: 9322632
Drug: Misoprostol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (25 microgram tablets every 4 hours for a maximum of six doses)
Study: 9322632
Drug: Dinoprostone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (10 mg vaginal insert for a maximum of 24 hours)
Study: 7993573
Drug: High-dose OKT3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose OKT3 (5 mg)
Study: 3054035
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (55 mg/kg/day for 5 days)
Study: 28096757
Drug: PWS +
Normalized name: Pulsed Wave Stimulation Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWS + S (pre-workout dietary supplement with synephrine)
Study: 16797309
Drug: Vardenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil treatment
Study: 11023085
Drug: BCAA 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA 150 g daily
Study: 11023085
Drug: Standardized diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized diet with 80 g protein daily
Study: 9407258
Drug: Gamma-oryzanol supplementation
Normalized name: GAMMA ORYZANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-oryzanol supplementation (500 mg.day-1)
Study: 3918190
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin for 72 hours
Study: 30252895
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial pulsed electromagnetic field treatment (squared bipolar 3 ms pulses, 50 Hz) for 30 min/day for 8 weeks